#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets

#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets

Submitted by admin on June 6, 2022 - 10:31am
Source: 
Endpoints
News Tags: 
ASCO 2022
CG Oncology
Merck
Keytruda
EQRx
sugemalimab
Headline: 
#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets
snippet: 

CG Oncology attracted some attention last month at #AACR22 for its early data on its oncolytic virus paired with Merck’s Keyrtruda for bladder cancer, and updated numbers from ASCO don’t disappoint.

Do Not Allow Advertisers to Use My Personal information